Cargando…

The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1

We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okamura, Takuro, Hashimoto, Yoshitaka, Osaka, Takafumi, Fukuda, Takuya, Hamaguchi, Masahide, Fukui, Michiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	the Society for Free Radical Research Japan 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667382/ https://www.ncbi.nlm.nih.gov/pubmed/31379410 http://dx.doi.org/10.3164/jcbn.18-114

Ejemplares similares

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
por: Hata, Shinnosuke, et al.
Publicado: (2022)

The role of chicken eggs in modulating sarcopenic obesity and gut microbiota in db/db mice
por: Okamura, Takuro, et al.
Publicado: (2023)

Reduction of Fat to Muscle Mass Ratio Is Associated with Improvement of Liver Stiffness in Diabetic Patients with Non-Alcoholic Fatty Liver Disease
por: Osaka, Takafumi, et al.
Publicado: (2019)

Milk protects against sarcopenic obesity due to increase in the genus Akkermansia in faeces of db/db mice
por: Okamura, Takuro, et al.
Publicado: (2023)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Effects of Royal Jelly on Gut Dysbiosis and NAFLD in db/db Mice
por: Kobayashi, Genki, et al.
Publicado: (2023)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
por: Saijo, Yuto, et al.
Publicado: (2023)

Let-7e-5p Regulates IGF2BP2, and Induces Muscle Atrophy
por: Okamura, Takuro, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease remission in men through regular exercise
por: Osaka, Takafumi, et al.
Publicado: (2018)

Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study
por: Munekawa, Chihiro, et al.
Publicado: (2022)

Lepr(db/db) Mice with Senescence Marker Protein-30 Knockout (Lepr(db/db)Smp30(Y/−)) Exhibit Increases in Small Dense-LDL and Severe Fatty Liver Despite Being Fed a Standard Diet
por: Kondo, Yoshitaka, et al.
Publicado: (2013)

Handgrip measurement as a useful benchmark for locomotive syndrome in patients with type 2 diabetes mellitus: A KAMOGAWA‐DM cohort study
por: Kitagawa, Noriyuki, et al.
Publicado: (2020)

Triglyceride–glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study
por: Okamura, Takuro, et al.
Publicado: (2020)

Visceral Adiposity Index is a predictor of incident colorectal cancer: a population-based longitudinal study
por: Okamura, Takuro, et al.
Publicado: (2020)

Effect of alcohol consumption and the presence of fatty liver on the risk for incident type 2 diabetes: a population-based longitudinal study
por: Okamura, Takuro, et al.
Publicado: (2020)

Creatinine to Body Weight Ratio Is Associated with Incident Diabetes: Population-Based Cohort Study
por: Hashimoto, Yoshitaka, et al.
Publicado: (2020)

Changes in metabolic complications in patients with alcoholic fatty liver disease monitored over two decades: NAGALA study
por: Hamaguchi, Masahide, et al.
Publicado: (2020)

Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study
por: Okamura, Takuro, et al.
Publicado: (2021)

Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy
por: Osaka, Takafumi, et al.
Publicado: (2023)

Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes
por: Hashimoto, Yoshitaka, et al.
Publicado: (2022)

Renoprotective Effect of Formononetin by Suppressing Smad3 Expression in Db/Db Mice
por: Lv, Jiawei, et al.
Publicado: (2020)

A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes
por: Fukuda, Takuya, et al.
Publicado: (2020)

A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men
por: Nakanishi, Naoko, et al.
Publicado: (2021)

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
por: Hashimoto, Yoshitaka, et al.
Publicado: (2021)

Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study
por: Yoshitaka, Hashimoto, et al.
Publicado: (2017)

Partially Hydrolyzed Guar Gum Suppresses the Development of Sarcopenic Obesity
por: Okamura, Takuro, et al.
Publicado: (2022)

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
por: Terami, Naoto, et al.
Publicado: (2014)

Japanese radio calisthenics prevents the reduction of skeletal muscle mass volume in people with type 2 diabetes
por: Kimura, Tomonori, et al.
Publicado: (2020)

Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study
por: Sakai, Ryosuke, et al.
Publicado: (2018)

Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study
por: Yoshimura, Yuta, et al.
Publicado: (2021)

The Association of Salt Intake and Non-alcoholic Fatty Liver Disease in People With Type 2 Diabetes: A Cross-Sectional Study
por: Takahashi, Fuyuko, et al.
Publicado: (2022)

Microbe‐associated metabolites as targets for incident type 2 diabetes
por: Hashimoto, Yoshitaka, et al.
Publicado: (2020)

Fermented soybean foods and diabetes
por: Hashimoto, Yoshitaka, et al.
Publicado: (2023)

Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression
por: Shao, Yimin, et al.
Publicado: (2015)

Epigallocatechin-3-gallate Attenuates Renal Damage by Suppressing Oxidative Stress in Diabetic db/db Mice
por: Yang, Xiu Hong, et al.
Publicado: (2016)

EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation
por: Ha, Kyung Bong, et al.
Publicado: (2022)

Exogenous Spermidine Alleviates Diabetic Myocardial Fibrosis Via Suppressing Inflammation and Pyroptosis in db/db Mice
por: Wei, Can, et al.
Publicado: (2023)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jn3q17tos5kj1i0kp5g052too1